42 results about "Chemerin" patented technology

The invention discloses a GPR1 antagonistic polypeptide and a derivative and application thereof and particularly relates to a GPR1 antagonistic polypeptide shown in SEQ ID No.1-5 and a derivative thereof. The derivative of the binding peptide is a product obtained in the mode that conventional modification is conducted on a GPR1 binding peptide amino acid side chain group and an amino terminal ora carboxyl terminal of a GPR1 antagonistic polypeptide fragment or a product obtained in the mode that a label for detection or purification of polypeptide or protein is linked to the GPR1 antagonistic polypeptide. The binding peptide and the derivative thereof can be combined with GPR1 in vitro, by stopping combination of chemerin and GPR1, increase of the cAMP concentration is promoted, the (Ca2+) influx caused by chemerin is inhibited, effective micromolecule treatment drugs are provided for diseases, such as breast cancer, of high-expression GPR1 receptors, and the GPR1 antagonistic polypeptide can be widely applied in the fields of medicine and biology.

The invention discloses a CMKLR1 antagonistic polypeptide and its derivatives and applications, specifically related to the sequence of SEQ ID No.1‑9 and its derivatives. The derivatives of the binding peptide are CMKLR1 binding peptide amino acid side chain group, CMKLR1 The product obtained by conventional modification of the amino-terminal or carboxyl-terminal of the antagonistic polypeptide fragment, or the product obtained by linking a tag for polypeptide or protein detection or purification on the CMKLR1 antagonistic polypeptide; the binding peptide and its derivatives can bind CMKLR1 in vitro , by blocking the combination of chemerin / RvE1 and CMKLR1 to change the concentration of cAMP, inhibit the calcium influx caused by chemerin, and inhibit the cell chemotaxis caused by chemerin, and provide effective therapeutic small molecule drugs for diseases with high expression of CMKLR1 receptors.

The invention discloses a CMKLR1 antagonistic polypeptide and its derivatives and applications, specifically related to the sequence of SEQ ID No.1‑24 and its derivatives, the derivatives of the binding peptide are CMKLR1 binding peptide amino acid side chain group, CMKLR1 The product obtained by conventional modification of the amino-terminal or carboxyl-terminal of the antagonistic polypeptide fragment, or the product obtained by linking a tag for polypeptide or protein detection or purification on the CMKLR1 antagonistic polypeptide; the binding peptide and its derivatives can bind CMKLR1 in vitro , by blocking the combination of chemerin / RvE1 and CMKLR1, it promotes the increase of cAMP concentration, inhibits the calcium influx caused by chemerin, inhibits the cell chemotaxis caused by chemerin, and can inhibit the proliferation of ovarian cancer cells and promote the apoptosis of ovarian cancer cells. Small molecule drugs provide effective treatments for female reproductive diseases such as ovarian cancer.

Disclosed are method for treating diabetes, a protein for treatment of diabetes, and pharmaceutical composition comprising the same. The protein is human mature chemerin, which can be used to treat diabetes, in particular type 2 diabetes, inter alia to treat diabetes in a patient who is concurrently administered with insulin.

The invention relates to a test strip for detecting chemokine and its derivative polypeptide and a preparation method thereof, and specifically discloses a test strip for detecting chemokine, which includes a detection membrane, and the upstream of the detection membrane is provided with a The binding area of ​​the first antibody, the binding area is provided with a sample application area upstream, wherein, the detection membrane is provided with a detection area and a control area, and the control area is located downstream of the detection area; wherein the detection area is coated with a second antibody, The control region is coated with a secondary antibody containing an anti-first antibody; both the first antibody and the second antibody can specifically bind to chemokines. The test strip of the invention is convenient, fast, economical and can realize semi-quantitative.

The invention discloses a method for detecting single nucleotide polymorphism of a cattle chemerin gene. Gene polymorphism comprises A or G base polymorphism in the 868th site of the cattle chemerin gene and G or A base polymorphism in the 1021st site of the cattle chemerin gene. The detection method for the single nucleotide polymorphism of the cattle chemerin gene comprises the following steps of: by using a cattle entire genome DNA (deoxyribonucleic acid) to be detected, containing a chemerin gene, as a template, and a primer pair (comprising P and newP) as primers, carrying out PCR (Polymerase Chain Reaction) amplification on the cattle chemerin gene; after a PCR amplified product is digested by using restriction enzyme Pvu II, carrying out agarose gel electrophoresis on an amplified fragment subjected to enzyme digestion; and identifying the single nucleotide polymorphism of the 868th site and the 1021st site of the cattle chemerin gene according to an agarose gel electrophoresisresult. The method is used for screening and detecting a molecular genetic marker which is closely related to cattle production trait on the basis of a DNA level, carrying out marker assisted selection (MAS) on Chinese cattle beef growth trait and quickly establishing cattle specie groups with favorable genetic resources.

This invention provides the use of one or more peptides derived from the C-terminal end of a Chemerin protein, or analogs or derivatives thereof for treatment of inflammation and / or endotoxic shock and / or treatment of wounds and / or reduction of levels of inflammatory chemokines in a subject, and one or more peptides derived from the C-terminal end of a Chemerin protein, or analogs or derivatives thereof for use in the treatment of inflammation and / or endotoxic shock, and / or wounds, or for the reduction of levels of inflammatory mediators.

The invention discloses a CMKLR1 antagonistic polypeptide and its derivatives and applications, specifically related to the sequence of SEQ ID No.1-17 and its derivatives, the derivatives of the binding peptide are CMKLR1 binding peptide amino acid side chain group, CMKLR1 The product obtained by conventional modification of the amino-terminal or carboxyl-terminal of the antagonistic polypeptide fragment, or the product obtained by linking a tag for polypeptide or protein detection or purification on the CMKLR1 antagonistic polypeptide; the binding peptide and its derivatives can bind CMKLR1 in vitro , by blocking the combination of chemerin and CMKLR1, it promotes the increase of cAMP concentration, inhibits the calcium influx caused by chemerin, inhibits the cell chemotaxis caused by chemerin, and can inhibit the proliferation of ovarian cancer cells, block their cell cycle, and promote the occurrence of ovarian cancer cells Apoptosis, providing effective therapeutic small molecule drugs for female reproductive diseases such as ovarian cancer.

The invention discloses a GPR1 antagonistic polypeptide and a derivative and application thereof and particularly relates to a GPR1 antagonistic polypeptide shown in SEQ ID No.1-3 and a derivative thereof. The derivative of the binding peptide is a product obtained in the mode that conventional modification is conducted on a GPR1 binding peptide amino acid side chain group and an amino terminal ora carboxyl terminal of a GPR1 antagonistic polypeptide fragment or a product obtained in the mode that a label for detection or purification of polypeptide or protein is linked to the GPR1 antagonistic polypeptide. The binding peptide and the derivative thereof can be combined with GPR1 in vitro, by stopping combination of chemerin and GPR1, increase of the cAMP concentration is promoted, the (Ca2+) influx caused by chemerin is inhibited, proliferation of breast cancer cells can be inhibited, the cell cycle of the breast cancer cells is blocked, apoptosis of the breast cancer cells is promoted, effective micromolecule treatment drugs are provided for female reproductive diseases such as breast cancer, and the GPR1 antagonistic polypeptide can be widely applied in the fields of medicine and biology.